InKine Gets $1 Million Payment From Zeria
InKine Pharmaceutical Co. Inc. said it received a $1 million milestone payment from Zeria Pharmaceutical Co., which is serving as InKine's licensee for the company's sodium phosphate tablets in Japan. The Blue Bell, Pa., biopharmaceutical company markets the colonic purgative tablets, under the brand name Visicol, in the United States as a bowel cleansing agent. InKine is also seeking to market the drug as a laxative for patients with constipation.
Philadelphia Business Journal (http://www.bizjournals.com/philadelphia/stories/2005/03/28/daily14.html)